Close Menu

Bar Harbor BioTechnology

BRB, which is also developing similar tests for other cancers and autoimmune diseases, has partnered with lab testing services firm Clinical Reference Laboratory for clinical validation of its tests.

The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.

In an interview with PCR Insider, Greg Shipley, director of the Quantitative Genomics Core Laboratory at University of Texas Health Science Center at Houston, discussed the technique and how UTHSCH researchers are using it.

BHB, founded in 2006, is betting that the new service offering will generate both new revenues and additional sales of its StellARray and XenoQ plate-based PCR kits.

Bar Harbor Biotechnology will offer real-time PCR services to researchers using its StellARrays and XenoQ assays.

Lonza is distributing Bar Harbor BioTechnology's new tools under an exclusive agreement.

Product Watch: Jan 21, 2010

Premium

Bar Harbor's XenoQ assays

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.